30 anni di energia salutare per tutta la pelle
Continuare a progettare il futuro della medicina estetica
(1996-2005)
The Science Comes First
The laser industry had a skin tone problem.
We spent nearly a decade solving it - engineering 650-micropulse pulse technology that made safe treatments across all Fitzpatrick skin types possible for the first time.
We chose to be right, not first.
• 1996
Aerolase founded with a singular misson: create laser technology safe for all skin types.
• 2000
First FDA clearance.
• 2004
Expanded FDA clearances across multiple indications.
• 2005
LightPod Neo & LightPod Era platforms established.
Nine years. Zero shortcuts. The science was proven before commercial pressure ever entered the equation.
We expanded geographically before we expanded commercially.Validazione globale attraverso l'eccellenza clinica.
• 2006–2011
U.S. dermatology market entry with clinical research and proof of concept.
• 2012–2015
Additional FDA clearances for Neo; Medical Advisory Board formed; peer-reviewed publications.
Every adoption was intentional. Every case study was a proof point.Lasciamo che siano i risultati clinici, non i budget di marketing, a guidare l'adozione. La tecnologia si è dimostrata valida nelle condizioni più impegnative.
Ci siamo espansi geograficamente prima di espanderci commercialmente, ottenendo l'adozione di KOL e sviluppando casi di studio su diverse popolazioni di pazienti in tutto il mondo.
(2006-2015)
Dimostrando che funziona ovunque
We didn't chase volume — we chose our first customers as carefully as we'd chosen our technology. Clinical outcomes, not marketing budgets, drove adoption.
(2016-2021)
From Clinic to the World Stage
With clinical validation in hand, we expanded internationally and launched the next generation of laser platforms.
From proof of concept to product launch.
• 2016–2017
International expansion into Europe, the Middle East, Asia and Africa.
• 2018
Neo Elite, Era Elite and Neo V launched.
• 2019–2021
North America commerical infrastructure built out.
From Technology pioneer to market leader.
• 2022
Major sales expansion across North America , Exci308 added to the Aerolase technology portfolio, business plan to target Dermatologists, Plastic Surgeons, and Aestheticians.
• 2023
Australia market development, expanded KOL network across all specialties.
• 2024
Matured sales infrastructure and market segmentation, formalized customer success programs.
• 2025
Hybrid Fractional Era launched, Aerolase India established, Era Focus in development.
(2022-2025)
Building the Engine to Scale
The science was undeniable — now we built the commercial engine to match it.
(2026+)
The Confidence Era
Proving what 30 years of precision enables.
Three decades of physics-first innovation. One unwavering commitment: healthy energy that works for every patient, every time.
The Next 30 Years
We're not just celebrating where we've been. We're defining where the industry is going!
Tre decenni di impatto
Più di 3000
Pratiche servite.
1 M
Pazienti trattati.
50+
Paesi raggiunti.
I-VI
Tipi di pelle trattati in modo sicuro.
30 Years, In Their Words
«Per molto tempo abbiamo cercato dispositivi sicuri ed efficaci per una varietà di tonalità della pelle. Per i pazienti con pelle più scura che necessitano di epilazione, ringiovanimento, trattamento dei vasi sanguigni e contusioni, non avevamo quel dispositivo fino all'arrivo di Aerolase. È sicuro ed efficace e posso usarlo su qualsiasi paziente».
